The reversion of TAMs improved the effect of anti‐PD‐L1 cancer immunotherapy by suppressing STAT6 and/or activating nuclear factor‐κB 80, 81, suggesting blockade of B7‐H4, PD1, or PD‐L1 as an approach for tumor therapy. Here, VTCN1 is linked to cancer.